A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies

Area of Science:

• Molecular Biology
• Oncology
• Genomics

Background:

• Gene expression profiling aids cancer therapy selection.
• Acute myeloid leukemia (AML) requires precise treatment stratification.

Purpose of the Study:

• Develop a rapid qPCR platform for AML companion diagnostics.
• Predict patient response to intensive chemotherapy and hypomethylating agent plus venetoclax (HMA+Ven).

Main Methods:

• Developed a qPCR-based platform profiling cell state, stemness, and BCL2 family genes.
• Validated signatures across platforms and patient samples from two centers.
• Integrated gene expression signatures with clinical and genetic features.

Main Results:

• Signatures demonstrated stability and utility.
• Expression levels of promonocyte-like signature and BCL2 predict response and survival in HMA+Ven treated patients.
• Multivariable models incorporating genetic features confirmed predictive value.

Conclusions:

• The rapid profiler enhances treatment stratification for newly diagnosed AML patients.
• Prospective incorporation may improve patient outcomes.
• Companion diagnostics are crucial for personalized AML therapy.